Thirty-one percent of Americans are hypertensive, 30% are prehypertensive, and approximately 20% are hypertensive yet unaware of their status. 1,2 Only 47% of those with hypertension are adequately controlled. 1 Prior research shows that diet and lifestyle modifications, including physical activity, sodium reduction, and fish oil supplementation, can reduce blood pressure (BP), enhance antihypertensive drug efficacy, and decrease cardiovascular disease (CVD) risk. 3 The active ingredients in fish oil considered responsible for its antihypertensive effect are the long-chain omega-3 fatty acids eicosapentaenoic acid (EPA; 20:5 n-3) and docosahexaenoic acid (DHA; 22:6 n-3). Although previous meta-analyses of fish oil supplementation and BP have been published, 4-7 none have been designed with inclusion criteria sufficient to examine the extensive scope of literature available in this active area of investigation. For example, the most recently published meta-analysis excluded trials that examined food sources of EPA and DHA (herein referred to as EPA+DHA) and those that were less than 8 weeks in duration. 7 Therefore, our main objective was to update the state of the science by conducting the most comprehensive meta-analysis of its kind of randomized controlled trials (RCTs) that examined EPA+DHA in relation to BP. background Although a large body of literature has been devoted to examining the relationship between eicosapentaenoic and docosahexaenoic acids (EPA+DHA) and blood pressure, past systematic reviews have been hampered by narrow inclusion criteria and a limited scope of analytical subgroups. In addition, no meta-analysis to date has captured the substantial volume of randomized controlled trials (RCTs) published in the past 2 years. The objective of this meta-analysis was to examine the effect of EPA+DHA, without upper dose limits and including food sources, on blood pressure in RCTs.
METHODS

Literature review
A comprehensive literature search was conducted by the University of Colorado Denver Health Science Library using Ovid/Medline, Embase, and the Cochrane Library. A PubMed search was performed in February 2013 to identify any publications not yet indexed by Ovid/Medline. Literature searches covered studies published from 1946 through February 2013 and published in all languages. Level 1 screening included review of all titles and/or abstracts. Full-text publications of any studies not eliminated at level 1 were retrieved for complete review at level 2 screening. Supplementary literature searches included examining the reference lists of all relevant studies, pertinent review articles, and meta-analyses.
Eligibility criteria for study selection
Included studies were RCTs that examined the effect of EPA+DHA on BP in nonhospitalized adults (aged ≥18 years). Eligible outcomes were systolic and diastolic BP values (SBP and DBP, respectively). The exclusion criteria in this review were as follows:
1. Hypertensive subjects treated with BP-lowering medications; 2. Less than 3-week treatment duration; 3. Crossover RCTs with less than a 4-week washout period between treatments; 4. Studies that did not specify the amount of EPA+DHA provided or without required data to be used meta-analytically (all authors of otherwise eligible studies were contacted for missing data); and 5. Studies conducted in populations not representative of the general adult population, including pregnant and nursing women and individuals with preexisting CVD or significant disease process (e.g., renal disease or cancer) or secondary hypertension.
Data extraction and quality assessment
The following qualitative and quantitative information was extracted from all RCTs: publication year, population demographic characteristics, geographic location, baseline hypertensive status, other relevant baseline health characteristics, medication use, sample size, the specific dose of EPA+DHA, the type of food or supplement, outcome assessment method, and means and SDs for BP outcomes.
Data synthesis
Random-effects meta-analysis models were used to calculate weighted group mean differences (postintervention minus preintervention), 95% confidence intervals (CIs), and corresponding P values for heterogeneity between the EPA+DHA group and the placebo group. The weight of each study was based on the inverse of the variance, which is a measure that accounts for the sample size in each group. The macro-level models included data on all subjects at all dose levels. Subgroup analyses were conducted to identify potential sources of heterogeneity or between-study variability and to estimate the effect of EPA+DHA according to key study characteristics. Categorical dose-response analyses were performed to discern potential patterns or thresholds of effect. Sensitivity and influence analyses were conducted by evaluating the impact of adding or removing studies based on important study characteristics and outlier status. The relative weight of each study was appreciated for each meta-analysis model to determine the influence that each study had on the overall summary effect. The presence of publication bias was assessed visually by examining a funnel plot measuring the SE as a function of effect size, as well as performing Egger's regression method and the Duval and Tweedie imputation method. 8 All analyses were performed using Comprehensive Meta-Analysis (version 2.2.046; Biostat, Englewood, NJ).
RESULTS
Study Characteristics
A flow diagram of the search strategy, including reasons for exclusion, is shown in Figure 1 . A total of 70 RCTs 9-78 met all eligibility criteria and were included in the metaanalysis. The main study characteristics are shown in Table 1 (hypertensive populations) and Table 2 (normotensive populations, with 1 prehypertensive population). 17 Ramel et al. 63 examined hypertensive and normotensive subjects combined; these data are included in Table 1 but were not metaanalyzed in the subgroup analyses by hypertension status. Approximately 40% of the included RCTs were conducted in North America, with the remaining distributed primarily between Nordic countries (20%), European countries other than the Nordic countries (27%), and Australia (13%). The mean study duration was 69 days, the mean EPA+DHA dose was 3.8 g/day, and sources of EPA+DHA included different types of seafood, EPA+DHA-fortified foods, fish oil, algal oil, and purified ethyl esters. Olive oil was the most commonly used placebo, with the remainder consisting predominately of other vegetable oils (e.g., safflower, corn, and sunflower oils).
Results from meta-analysis
Meta-analysis results for all analyses are reported in Table 3 , and results for selected analyses are illustrated in Figures 2 and 3 and Supplementary Figures S1 and S2 .
In the overall meta-analysis model of 93 data points from 70 RCTs, SBP decreased by 1.52 mm Hg (95% CI = −2.25 to −0.79) and DBP by 0.99 mm Hg (95% CI = −1.54 to −0.44), compared with placebo, after EPA+DHA provision (Table 3 ; Supplementary Figures S1 and S2) . Studies with multiple entries in the meta-analysis models reflect results presented separately by the authors for different subgroups (e.g., low-dose and high-dose EPA+DHA). In the metaanalysis of hypertensive subjects, significant reductions in SBP (−4.51 mm Hg; 95% CI = −6.12 to −2.83) and DBP (−3.05 mm Hg; 95% CI = −4.35 to −1.74) were observed ( Figure 2) . The meta-analysis of studies among normotensive subjects also found a significant reduction of SBP (−1.25 mm Hg; 95% CI = −2.05 to −0.46) and DBP (−0.62 mm Hg; 95% CI = −1.22 to −0.02) ( Table 3 ). The summary estimates were modified by source of EPA+ DHA and by study region ( The subgroup analyses by dose are depicted in Figure 3 . There was no clear pattern of dose-response between EPA+DHA and SBP. Significant reductions were observed with doses of 1 to <2 g/d (−1.81; 95% CI = −3.59 to −0.03) and 3 to <4 g/d (−3.85; 95% CI = −5.55 to −2.15). No apparent effect on DBP was observed for dose levels <2 g/day, whereas significant reductions were observed for 2 to <3 g/ day (−1.09; 95% CI = −2.08 to −0.11) and 3 to <4 g/day (−1.86; 95% CI = −2.67 to −1.06).
An examination of potential publication bias indicated a modest proclivity for published studies that found a significant SBP reduction with EPA+DHA provision (Supplementary Figure S3 ). There was a slight indication of publication bias with a proclivity for publication of results that showed a significant DBP reduction with EPA+DHA provision, which was modified by study region. Non-US studies were more likely to publish findings showing DBP reduction with EPA+DHA provision, whereas US studies were more likely to publish null findings or an increase in DBP with EPA+DHA provision.
DISCUSSIOn
This meta-analysis of RCTs that examined EPA+DHA provision and BP provides the most comprehensive quantitative summary of the evidence to date. Before this meta-analysis, the most recent published meta-analysis 7 excluded studies <8 weeks in duration and those that examined food sources of EPA+DHA. By liberalizing the duration restriction to 3 weeks, including RCTs conducted with EPA+DHA-rich and -fortified foods, and capturing recent RCTs published in the past 2 years, our meta-analysis evaluated an additional 53 studies not included by Campbell et al. 7 The considerably larger volume of studies enhanced the statistical power to perform important subgroup analyses by factors such as dose, geographic region, hypertensive status, and source of EPA+DHA.
The results from our analysis demonstrate that EPA+DHA are as effective, and in some cases more effective, than other lifestyle-related interventions, including increasing physical activity and restricting alcohol and sodium, 79 for lowering BP among hypertensive populations not taking antihypertensive medication. These results are consistent with findings from Campbell et al. 7 as well as other earlier meta-analyses. 80, 81 Lowered systemic vascular resistance through changes in endothelial function is considered a primary mechanism by which EPA+DHA may lower BP. 82 Recent systematic reviews and a meta-analysis of RCTs found improved endothelial function in response to EPA+DHA, particularly among The total sample size is shown plus M+F to indicate both men and women were included when the distribution by sex was not provided. patients with risk factors for CVD, including hypertension, but not consistently among healthy young and middleaged subjects. 83, 84 This observation may explain the greater response of unmedicated hypertensive subjects when compared with normotensive subjects in our meta-analysis. The reductions in BP observed in this analysis are not only statistically significant but also are clinically meaningful. Among adults, SBP rises by approximately 0.6 mm Hg per year; among those aged ≥50 years, the lifetime risk of hypertension is 90%. 85 Furthermore, only 1 mm Hg SBP separates each stage of hypertension. The statistically significant reduction in SBP of 1.25 mm Hg noted among normotensive individuals in our analysis would represent a delay of agerelated SBP increase by 2 years and progression from prehypertensive to hypertensive status. The 4.51 mm Hg decrease observed among hypertensive populations not taking antihypertensive medication could prevent an individual from requiring medication to control their hypertension or could help maintain an individual in a lower stage of progressive hypertension. Lowered systemic vascular resistance and BP can reduce risk of coronary plaque rupture, stroke, and complications of stroke, including related cognitive decline, thus improving clinical outcomes for higher-risk populations. 82 Overall, there was no clear discernible pattern of a doseresponse effect for EPA+DHA on BP, which is similar to findings from past meta-analyses. 7, 81, 86 Although less data are available that examine EPA+DHA-rich or -fortified food and BP outcomes (n = 8 studies in this meta-analysis), EPA+DHA-rich or -fortified foods were less effective than supplements with regards to lowering BP. It is important to note, however, that there are barriers to frequent fish consumption, which may explain in part the discrepant findings between food and supplement studies. Among the general population, barriers to frequent fish consumption include dislike of taste, unpleasant smell, and "concerns about bones. " 87, 88 Five of the 8 food studies in the current meta-analysis required daily consumption of oily fish, including sardines, mackerel, and salmon. Although compliance was not routinely reported among all food studies, von Houwelingen et al., 75 who provided subjects with mackerel, reported compliance of only 78%. In Figure 3 . Results from meta-analyses of randomized controlled trials examining eicosapentaenoic and docosahexaenoic acids (EPA+DHA) and (a) systolic blood pressure and (b) diastolic blood pressure by EPA+DHA dose category. The circle represents the pooled summary estimate across all studies within each dose category, with 95% confidence intervals (CIs). n indicates the number of data points in each dose category, which may be greater than the number of individual studies.
addition, the researchers noted that a tendency for compliance decreased over the course of the study, as assessed by urinary lithium excretion. Only 3 studies of EPA+DHA-fortified foods (e.g., margarine and bread) 29, 55, 65 were identified for inclusion in our meta-analysis, which challenges efforts to fully investigate the role of these EPA+DHA sources as part of an overall healthy dietary pattern.
Collectively, the evidence from RCTs indicates that provision of ≥2 g/d EPA+DHA may reduce both SBP and DBP, with the strongest benefits observed among hypertensive individuals who are not on antihypertensive medication. In addition, a lower dose (between 1 and 2 g/d) may reduce SBP but not DBP. From a clinical and public health perspective, provision of EPA+DHA may lower BP and ultimately reduce the incidence of associated chronic diseases.
SUPPLEMEnTARY MATERIAL
Supplementary materials are available at American Journal of Hypertension (http://ajh.oxfordjournals.org).
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